<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02870231</url>
  </required_header>
  <id_info>
    <org_study_id>NN9030-4130</org_study_id>
    <secondary_id>U1111-1175-7040</secondary_id>
    <nct_id>NCT02870231</nct_id>
  </id_info>
  <brief_title>Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity</brief_title>
  <official_title>A Multiple Dose Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in the United States of America. The aim of this trial is to
      investigate Safety, Tolerability, PK (the exposure of the trial drug in the body) and PD (the
      effect of the investigated drug on the body) for Multiple Doses of NNC9204-0530 in
      Combination with Liraglutide in Male and Female Subjects being Overweight or with Obesity
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 18, 2016</start_date>
  <completion_date type="Actual">September 3, 2017</completion_date>
  <primary_completion_date type="Actual">September 3, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment emergent adverse events</measure>
    <time_frame>Day 1-112</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the NNC9204-0530 serum concentration-time curve</measure>
    <time_frame>Day 84-112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum serum concentration of NNC9204-0530</measure>
    <time_frame>Day 84-112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1C</measure>
    <time_frame>Day -1, Day 85</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">187</enrollment>
  <condition>Metabolism and Nutrition Disorder</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>NNC9204-0530 / Placebo and Liraglutide 1.8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NNC9204-0530 /Placebo and Liraglutide 3.0</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC9204-0530</intervention_name>
    <description>Once-daily subcutaneous (s.c., under the skin) administration.</description>
    <arm_group_label>NNC9204-0530 / Placebo and Liraglutide 1.8</arm_group_label>
    <arm_group_label>NNC9204-0530 /Placebo and Liraglutide 3.0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Once-daily subcutaneous (s.c., under the skin) administration.</description>
    <arm_group_label>NNC9204-0530 / Placebo and Liraglutide 1.8</arm_group_label>
    <arm_group_label>NNC9204-0530 /Placebo and Liraglutide 3.0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Once-daily subcutaneous (s.c., under the skin) administration</description>
    <arm_group_label>NNC9204-0530 / Placebo and Liraglutide 1.8</arm_group_label>
    <arm_group_label>NNC9204-0530 /Placebo and Liraglutide 3.0</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index between 25.0 and 39.9 kg/m^2 (both inclusive) at screening.

          -  Male or female, age between 18 and 55 years (both inclusive) at the time of signing
             informed consent

        Exclusion Criteria:

          -  Any clinically significant weight change (equal or above 5% self-reported change) or
             dieting attempts (e.g. participation in an organized weight reduction program within
             the last 90 days prior to screening

          -  Any prior obesity surgery or currently present gastrointestinal implant.

          -  Thyroid-stimulating hormone (TSH) values outside 0.4-6.0 mIU/L

          -  Glycosylated haemoglobin (HbA1c)above or equal to 6.5% or in Syst√®me International
             (SI) units 48 mmol/mol

          -  Abnormal ECG (electrocardiogram) results including 2nd or 3rd degree AV-block,
             prolongation of the QRS complex above 120 ms, or the QTcF interval above 430 ms
             (males) or above 450 ms (females), or other clinically relevant abnormal results, as
             judged by the investigator

          -  A history of additional risk factors for Torsades de pointes (e.g., heart failure,
             hypokalaemia, family history of Long QT Syndrome)

          -  Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine
             neoplasia syndrome type 2 (MEN 2)

          -  Calcitonin above or equal to 50 ng/L

          -  History of pancreatitis (acute or chronic)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2016</study_first_submitted>
  <study_first_submitted_qc>August 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2016</study_first_posted>
  <last_update_submitted>September 8, 2017</last_update_submitted>
  <last_update_submitted_qc>September 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Nutrition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

